Prof. Dr. med. Dr. med. habil. Olaf G Wilhelm
Chief Executive Officer and Chairman of the Executive Management Board
Prof. Dr. med. Olaf G. Wilhelm is founder and Chief Executive Officer of Therawis Pharma GmbH, Munich. He also was co-founder of Wilex Biotechnology GmbH and its Managing Director from October 1, 1997 until April 8, 2001, and has been Chief Executive Officer of WILEX AG since April 9, 2001 since the conversion of the company into a stock market corporation (Wilex AG). Prof. Wilhelm managed two company acquisitions, several international development and commercialization partnerships and listed Wilex AG on the public stock Exchange. In the year 2001, he was appointed Extraordinary Professor of Gynecology at the Technical University of Munich. From 1990 to 1997, he was employed as senior physician for Obstetrics and Gynecological Oncology at the Dept. Obstetrics & Gynecology (Frauenklinik) at the Medical School of the university hospital Klinikum rechts der Isar des Klinikums rechts der Isar) at the Technical University of Munich. While at the Technical University of Munich, Prof. Wilhelm was also a member of the Clinical Research Unit of the Frauenklinik. From 1987 to 1990, he worked as a scientist for Eli Lilly and Company, Indianapolis, Indiana/USA. Prof. Wilhelm received the Midwest Trainee Award of the American Federation for Clinical Research and has authored over 70 publications. He received his MD from the Technical University of Munich. Prof. Wilhelm is a member of the senate of the “Bundeswirtschaftssenat des Bundesverbandes mittelständische Wirtschaft Deutschland e.V.” In 2011, the Technical University of Munich awarded him the title “TUM Entrepreneur of Excellence”.
Dr. Jochen Herbst
Dr. Jochen Herbst, co-founder of Therawis Pharma, has more than ten years of professional experience at his disposal. For several years, Mr. Herbst has worked in the New York and Duesseldorf offices of the international top-tier US law firm Shearman & Sterling. Afterwards Dr. Herbst has been equity partner in a regional mid-sized law. Also due to his performance contribution, this law firm has been choosen to be nominated Medium-sized Law Firm of the Year in Germany in 2007 by the publisher’s board of the well-known JUVE Verlag. Since 2003, Mr. Herbst is also acting as a lecturing professor at the University of Cologne. Dr. Herbst (co-)published numerous legal articles and two books. Dr. Herbst’s most recent publication is a law book on International Economic Law published by the prestigious German C. F. Müller Verlag. Dr. Herbst’s practice is focused on German general corporate and investment law, private equity, venture capital, funds, mergers, acquisitions and joint ventures. Dr. Herbst’s experience covers a wide array of industries (including biotechnology, life sciences, renewable energy chemicals, consulting business etc.). Dr. Herbst’s M&A, venture capital and capital markets experience includes numerous acquisitions, cross-border mergers (including publicly listed companies and funds), dual listings on stock exchanges both in Germany and the US, as well as financing rounds for venture capitalists (including tax structuring). He has also advised clients in joint ventures. Dr. Herbst regularly advises clients in the formation and structuring of early stage technology companies, particularly in the area of biotechnology, life sciences, health care, renewable energy and Consulting.
Dr. Roman Bartz
Head of Clinical & Medical Affairs
Dr. Roman Bartz, Head & Director Clinical Affairs of Therawis Pharma, has more than fifteen years of professional experience in clinical development especially in oncology. Between 2001 and 2014 Dr. Bartz was responsible at Wilex AG, an oncology focused biotech company, for clinical development of the antibody-based diagnostic imaging agent in renal cell carcinoma, including successful performance of a pivotal Phase III trial and for early clinical oncology trials of the small molecule program. In addition, he gained significant experience through interactions with regulatory authorities (FDA: pre-IND, IND, SPA, ODAC-meeetings and the EMA: Scientific Advise-meetings). Dr. Bartz was also in charge of Investigator Initiated Trials and organizing and supervising scientific advisory meetings and expert Meetings. From 1998-2001, he served as a lead-CRA for Kendle, a renowned international CRO in the Munich offices, where he was engaged in the conduct of several national and international clinical trials in various indications. From 1994 to 1998 Dr. Bartz worked at the Julius-Maximilians University of Würzburg, where he also earned his PhD at the Institute of Virology and Immunology.
Manager Finance & Operations
Marko Wilhelm has been with the company since 2014. He gained professional experience in the legal, marketing and finance departments of renowned companies. In March 2017 he was appointed Manager Finance & Operations at Therawis Pharma GmbH. Marko holds a Bachelor’s Degree in International Management from the FOM-University of Applied Sciences.